The standard surgical approach for all patients undergoing mastectomy for the treatment of non-invasive, ductal carcinoma in situ (DCIS) is to perform axillary lymph node staging through use of a traditional sentinel lymph node biopsy (SLNB) procedure where the lymph nodes that drain the breast first are removed at the time of mastectomy. This recommendation for traditional SLNB is due to the risk of finding invasive cancer during surgical evaluation of the mastectomy specimen and the inability to accurately map the lymphatic channels once the breast is removed. In a study by Herremans et al, the majority of traditional SLNBs were demonstrated to be unnecessary. By using Magtrace, a novel iron based lymphatic mapping agent, a delayed SLNB could eliminate these unnecessary traditional SLNBs. Magtrace, or superparamagnetic oxide (SPIO), was developed in 2018. Unlike traditional mapping agents of blue dye and technetium that clear the body within 24-48 hours, Magtrace remains in the lymph nodes for at least 4 weeks. Magtrace's ability to remain in the lymph node allows accurate mapping of the lymph nodes at the time of the mastectomy with the ability to return to the operating room for a delayed sentinel lymph node biopsy if invasive cancer is found on final pathology. This study will investigate whether the use of Magtrace will successfully allow patients with DCIS undergoing mastectomy to avoid undergoing SLNB.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Participants will receive a single injection of Magtrace into the breast during their mastectomy.
University of Florida
Gainesville, Florida, United States
RECRUITINGPercentage of patients with DCIS who do not undergo sentinel lymph node biopsy
Determine the percentage of patients with DCIS who do not undergo sentinel lymph node biopsy.
Time frame: 24 months post-mastectomy
Percentage of patients that are found to have invasive disease at time of mastectomy
Determine the Percentage of patients that are found to have invasive disease at time of mastectomy.
Time frame: At the time of mastectomy
Rate of return to operating room for delayed sentinel lymph node biopsy
Determine the number of patients who return to the operating room for delayed sentinel lymph node biopsy.
Time frame: 24 months post-mastectomy
Patient-reported outcomes measures
Compare the scores obtained to the historical control for each of the following scales of the Breast-Q questionnaire: psychosocial well-being, sexual well-being, cancer worry, fatigue, and impact on work.
Time frame: 24 months post-mastectomy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.